MyoGene Bio
Pre-clinicalDuchenne muscular dystrophy has no cure but ongoing research and clinical trials finally offer hope for this devastating muscle wasting disease. MyoDys45-55 is designed to permanently fix the underlying cause of the disease for half of all Duchenne patients using this single platform. Future
Market Cap
Private
Pipeline
—
Patents
—
Publications
—
Private Company
Total funding raised: $2.5M
About
Duchenne muscular dystrophy has no cure but ongoing research and clinical trials finally offer hope for this devastating muscle wasting disease. MyoDys45-55 is designed to permanently fix the underlying cause of the disease for half of all Duchenne patients using this single platform. Future
Gene TherapyRare DiseaseMuscular Disorders
Funding History
1Total raised:$2.5M
Seed$2.5MMay 15, 2021